- United States
- /
- Food and Staples Retail
- /
- NYSE:GRDN
Guardian Pharmacy Services Full Year 2024 Earnings: EPS Misses Expectations
Guardian Pharmacy Services (NYSE:GRDN) Full Year 2024 Results
Key Financial Results
- Revenue: US$1.23b (up 17% from FY 2023).
- Net loss: US$87.3m (down by 465% from US$23.9m profit in FY 2023).
- US$1.41 loss per share.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Guardian Pharmacy Services EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 48%.
In the last 12 months, the only revenue segment was Pharmacy Services contributing US$1.23b. Notably, cost of sales worth US$984.0m amounted to 80% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to US$302.9m (91% of total expenses). Explore how GRDN's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.8% growth forecast for the Consumer Retailing industry in the US.
Performance of the American Consumer Retailing industry.
The company's shares are down 2.4% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Guardian Pharmacy Services' balance sheet.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NYSE:GRDN
Guardian Pharmacy Services
A pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States.
Flawless balance sheet with moderate growth potential.
Market Insights
Community Narratives

